Clonal analysis of the quasispecies of antiviralresistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 77-85

  Karatayli, Ersin ^a   Idilman, Ramazan ^a   Karatayli, Senem C ^a   Cevik, Emrah ^a   Yakut, Mustafa ^a   Seven, Gülseren ^a   Kabaçam, Gökhan ^a   Bozdayi, A Mithat ^a   Yurdaydin, Cihan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOME, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874430056     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2294     Document Type: Article

References (25)

1. EASL Clinical Practice Guidelines. Management of chronic hepatitis. J Hepatol 2009; 50:227-242.
2. Lok ASF, McMahon BJ. AASLD practice guidelines: Chronic hepatitis B. Hepatology 2007; 45:507-539.
3. Yurdaydin C, Akarca US. Treatment of chronic hepatitis B with telbivudine: Wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. Liver Int 2011; 31:589-591.
4. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
5. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9:679-693.
6. Yurdaydin C. Entecavir: A step forward in combating hepatitis B disease. Expert Opin Pharmacother 2008; 9:3095-3109.
7. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
8. Hosaka T, Suzuki F, Suzuki Y, et al. Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudineresistant mutants of hepatitis B virus. Intervirology 2004; 47:362-369.
9. Karatayli E, Karayalçin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12:761-768.
10. Santantonio T, Fasano M, Durantel S, et al. Adefovir dipivoxil resistance patterns in patients with lamivudineresistant chronic hepatitis B. Antivir Ther 2009; 14:557-565.
11. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44:703-712.
12. Idilman R, Kaymakoglu S, Onder FO, et al. A short course of add-on adefovir dipivoxil treatment in lamivudineresistant chronic hepatitis B patients. J Viral Hepat 2009; 16:279-285.
13. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51:902-911.
14. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: Inluence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52:493-500.
15. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
16. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99-108.
17. Bozdayi AM, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149:2115-2129.
18. Günther S, Li BC, Miska S, et al. A novel method for eficient ampliication of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
19. Yang H, Westland C, Xiong S, Delaney WE 4th. In vitro antiviral susceptibility of full-length clinical hepatitis b virus isolates cloned with a novel expression vector. Antiviral Res 2004; 61:27-36.
20. Bozkaya H, Yurdaydin C, Idilman R, et al. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia. Antivir Ther 2005; 10:319-325.
21. Yatsuji H, Hiraga N, Mori N, et al. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol 2007; 79:1811-1817.
22. Villet S, Olliver A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46:531-538.
23. Tenney DJ. Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: Insight from entecavir resistance studies. Antivir Ther 2010; 15:529-535.
24. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical proile of viral rebound. Hepatology 2008; 48:88-98.
25. Pan CQ, Hu KQ, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat 2012; 19:213-219.